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background:  Vitamin K antagonists (VKAs) or the newer non-VKA oral anticoagulants (NOACs) are recommended for prevention of 
stroke in patients with atrial fibrillation (AF) and additional stroke risk factors. To assess changing patterns of antithrombotic therapy, 
GLORIA-AF Phase II collected data on patients with newly identified AF at risk of stroke (CHA2DS2VASc score ≥1) in routine care during 
the first 2 years after NOAC availability.
Methods:  Phase II of GLORIA-AF started after approval of dabigatran etexilate, the first NOAC available for stroke prevention in patients 
with AF. This cross-sectional analysis assesses treatment patterns in relation to patient age and CHA2DS2VASc score in North America 
(NA).
Results:  Of 3,415 patients with recent diagnosis of AF enrolled between Nov 2011 and Feb 2014, median age was 71 years, 44.8% were 
female, 80.4% had hypertension, 27.1% diabetes mellitus and 86.2% had CHA2DS2VASc scores ≥2. Patients were most often treated with 
VKA (26.1%), dabigatran (25.0%) or rivaroxaban (20.5%), followed by aspirin (13.5%) or apixaban (6.6%); 7.6% received no antithrombotic 
therapy. The relationships of antithrombotic therapy to stroke risk and age are shown.
conclusion:  This study describes the uptake of NOACs in NA during the first years of availability, with 52.1% of studied patients 
receiving these agents. VKA was still widely used, especially for elderly patients, and ~20% of patients <75 years old at high stroke risk 
(CHA2DS2VASc ≥2) were untreated or given aspirin alone.
 
